Patents Assigned to Transkaryotic Therapies, Inc.
-
Patent number: 7122354Abstract: DNA molecules comprising a sequence encoding the signal peptide of hGH linked to a heterologous protein and related cells, methods and fusion proteins.Type: GrantFiled: December 12, 2002Date of Patent: October 17, 2006Assignee: Transkaryotic Therapies, Inc.Inventors: Richard F. Selden, Marianne Borowski, Frances P. Gillispie, Carol M. Kinoshita, Douglas A. Treco, Melanie D. Williams
-
Patent number: 6924365Abstract: The present invention is directed to a synthetic nucleic acid sequence which encodes a protein wherein at least one non-common codon or less-common codon is replaced by a common codon. The synthetic nucleic acid sequence can include a continuous stretch of at least 90 codons all of which are common codons.Type: GrantFiled: September 28, 1999Date of Patent: August 2, 2005Assignee: Transkaryotic Therapies, Inc.Inventors: Allan M. Miller, Douglas A. Treco, Richard F Selden
-
Patent number: 6858578Abstract: Chimeric proteins useful in transporting a selected substance present in extracellular fluids, such as blood or lymph, into cells; quantitative assays for the selected substance using chimeric proteins; DNA encoding the chimeric proteins; plasmids which contain DNA encoding the chimeric proteins; mammalian cells, modified to contain DNA encoding the chimeric proteins, which express and, optionally, secrete the chimeric proteins; a method of producing the chimeric proteins; a method of isolating the chimeric proteins; a method of using the chimeric proteins to assay the selected substance; and a method of reducing extracellular levels of the selected substance through administration of the chimeric protein, which results in transport of the selected substance into cells.Type: GrantFiled: January 3, 2001Date of Patent: February 22, 2005Assignee: Transkaryotic Therapies, Inc.Inventors: Michael W. Heartlein, Jeffrey F. Lemontt, Michael F. Concino
-
Patent number: 6846676Abstract: The invention provides primary and secondary cells that are transfected with a nucleic acid molecule that encodes erythropoietin, clonal or heterogenous strains of such cells, and methods of producing these cell strains.Type: GrantFiled: June 8, 1999Date of Patent: January 25, 2005Assignee: Transkaryotic Therapies, Inc.Inventors: Richard F. Selden, Douglas Treco, Michael W. Heartlein
-
Publication number: 20040229250Abstract: This invention relates to methods and compositions for the diagnosis and treatment of Multiple Sulfatase Deficiency (MSD) as well as other sulfatase deficiencies. More specifically, the invention relates to isolated molecules that modulate post-translational modifications on sulfatases. Such modifications are essential for proper sulfatase function.Type: ApplicationFiled: February 10, 2004Publication date: November 18, 2004Applicant: Transkaryotic Therapies, Inc.Inventors: Kurt von Figura, Bernhard Schmidt, Thomas Dierks, Michael W. Heartlein, Maria Pia Cosma, Andrea Ballabio
-
Patent number: 6692737Abstract: The present invention relates to transfected primary and secondary somatic cells of vertebrate origin, particularly mammalian origin, transfected with exogenous genetic material (DNA) which encodes a desired (e.g., a therapeutic) product or is itself a desired (e.g., therapeutic) product, methods by which primary and secondary cells are transfected to include exogenous genetic material, methods of producing clonal cell strains or heterogenous cell strains, methods of gene therapy in which the transfected primary or secondary cells are used, and methods of producing antibodies using the transfected primary or secondary cells.Type: GrantFiled: April 13, 2000Date of Patent: February 17, 2004Assignee: Transkaryotic Therapies, Inc.Inventors: Richard F Selden, Douglas Treco, Michael W. Heartlein
-
Patent number: 6670178Abstract: The present invention relates to transfected primary and secondary somatic cells of vertebrate origin, particularly mammalian origin, transfected with exogenous genetic material (DNA) that encodes erythropoietin or an insulinotropin (e.g., derivatives of glucagon-like peptide 1 (GLP-1)), methods by which primary and secondary cells are transfected to include exogenous genetic material encoding erythropoietin or an insulinotropin, methods of producing clonal cell strains or heterogenous cell strains that express erythropoietin or an insulinotropin, methods of gene therapy, in which the transfected primary or secondary cells are used, and methods of producing antibodies using the transfected primary or secondary cells.Type: GrantFiled: April 19, 2000Date of Patent: December 30, 2003Assignee: Transkaryotic Therapies, Inc.Inventors: Richard F Selden, Douglas Treco, Michael W. Heartlein
-
Publication number: 20030152560Abstract: A therepeutic method whereby an individual suspected of having an &agr;-galactosidase A deficiency, such as Fabry disease, is treated either with (1) human cells that have been genetically modified to overexpress and secrete human &agr;-gal A, or (2) purified human &agr;-gal A obtained from cultured, genetically modified human cells.Type: ApplicationFiled: December 12, 2002Publication date: August 14, 2003Applicant: Transkaryotic Therapies Inc., a Massachusetts corporationInventors: Richard F. Selden, Marianne Borowski, Frances P. Gillispie, Carol M. Kinoshita, Douglas A. Treco, Melanie D. Williams
-
Publication number: 20030147868Abstract: The present invention relates to transfected primary, secondary, and immortalized cells of vertebrate origin particularly mammalian origin, transfected with exogenous genetic material (DNA) which encodes a desired (e.g., a therapeutic) product or is itself a desired (e.g., therapeutic) product, methods by which primary, secondary and immortalized cells are transfected to include exogenous genetic material, including DNA targeting by homologous recombination, methods for the activation and amplification of endogenous cellular genes, methods by which cells useful for large-scale protein production can be obtained, methods of producing clonal cell strains or heterogenous cell strains, and methods of gene therapy in which transfected primary, secondary or immortalized cells are used.Type: ApplicationFiled: November 18, 2002Publication date: August 7, 2003Applicant: Transkaryotic Therapies, Inc. a Delaware corporationInventors: Douglas Treco, Michael W. Heartlein, Richard F. Selden
-
Patent number: 6582391Abstract: An implantable device having a body of matrix material made up of insoluble collagen fibrils, and disposed therewithin (a) a plurality of vertebrate cells; and (b) a plurality of microspheres each of which consists primarily of one or more of the following materials: collagen, polystyrene, dextran, polyacrylamide, cellulose, calcium alginate, latex, polysulfone, or glass.Type: GrantFiled: July 2, 2002Date of Patent: June 24, 2003Assignee: Transkaryotic Therapies, Inc.Inventor: Rochelle Mineau-Hanschke
-
Publication number: 20030113894Abstract: The invention provides highly purified &agr;-Gal A, and various methods for purifying it; &agr;-Gal A preparations with altered charge and methods for making those preparations; &agr;-Gal A preparations that have an extended circulating half-life in a mammalian host, and methods for making same; and methods and dosages for administering an &agr;-Gal A preparation to a subject.Type: ApplicationFiled: June 10, 2002Publication date: June 19, 2003Applicant: Transkaryotic Therapies, Inc., a Delaware corporationInventors: Richard F. Selden, Marianne Borowski, Carol M. Kinoshita, Douglas A. Treco, Melanie D. Williams, Thomas J. Schuetz, Peter F. Daniel
-
Patent number: 6569681Abstract: The invention features a method of promoting an alteration at a selected site in a target DNA, e.g., in the chromosomal DNA of a cell. The method includes providing, at the site: (a) a double stranded DNA sequence which includes a selected DNA sequence; (b) an agent which enhances homologous recombination, e.g., a Rad52 protein or a functional fragment thereof; and (c) an agent which inhibits non-homologous end joining, e.g., an agent which inactivates Ku such as an anti-Ku antibody or a Ku-binding oligomer or polymer, and allowing the alteration to occur. The agent which inhibits non-homologous end joining, e.g., a Ku inactivating agent such as an anti-Ku antibody, is preferably provided locally. Components (a), (b), and (c) can be introduced together, which is preferred, or separately.Type: GrantFiled: March 14, 2000Date of Patent: May 27, 2003Assignee: Transkaryotic Therapies, Inc.Inventor: Evguenii Ivanov
-
Patent number: 6565844Abstract: The present invention relates to DNA constructs that alter the expression of a targeted gene in a cell when the DNA construct is homologously recombined with a target site within the chromosomal DNA of the cell, as well as to a cell into which has been incorporated a new transcription unit containing an exogenous regulatory sequence operatively linked to an endogenous gene of the cell's chromosomal DNA. These constructs and cells can be used in a method of altering expression of the targeted gene.Type: GrantFiled: May 14, 1999Date of Patent: May 20, 2003Assignee: Transkaryotic Therapies, Inc.Inventors: Douglas Treco, Michael W. Heartlein, Richard F Selden
-
Patent number: 6566099Abstract: A therapeutic method whereby an individual suspected of having an &agr;-galactosidase A deficiency, such as Fabry disease, is treated either with (1) human cells that have been genetically modified to overexpress and secrete human &agr;-gal A, or (2) purified human &agr;-gal A obtained from cultured, genetically modified human cells.Type: GrantFiled: January 27, 2000Date of Patent: May 20, 2003Assignee: Transkaryotic Therapies, Inc.Inventors: Richard F. Selden, Marianne Borowski, Frances P. Gillispie, Carol M. Kinoshita, Douglas A. Treco, Melanie D. Williams
-
Publication number: 20030091545Abstract: A composition having a body of matrix material made up of insoluble collagen fibrils, and disposed therewithinType: ApplicationFiled: May 31, 2002Publication date: May 15, 2003Applicant: Transkaryotic Therapies, Inc., Delaware CorporationInventor: Rochelle Mineau-Hanschke
-
Publication number: 20030077260Abstract: An implantable device having a body of matrix material made up of insoluble collagen fibrils, and disposed therewithinType: ApplicationFiled: July 2, 2002Publication date: April 24, 2003Applicant: Transkaryotic Therapies, Inc.Inventor: Rochelle Mineau-Hanschke
-
Publication number: 20030077806Abstract: The invention provides highly purified &agr;-Gal A, and various methods for purifying it; &agr;-Gal A preparations with altered charge and methods for making those preparations; &agr;-Gal A preparations that have an extended circulating half-life in a mammalian host, and methods for making same; and methods and dosages for administering an &agr;-Gal A preparation to a subject.Type: ApplicationFiled: June 7, 2002Publication date: April 24, 2003Applicant: Transkaryotic Therapies, Inc., a Delaware corporationInventors: Richard F. Selden, Marianne Borowski, Carol M. Kinoshita, Douglas A. Treco, Melanie D. Williams, Thomas J. Schuetz, Peter F. Daniel
-
Patent number: 6537542Abstract: The present invention relates to a method of gene or DNA targeting in cells of vertebrate, particularly mammalian, origin. That is, it relates to a method of introducing DNA into primary or secondary cells of vertebrate origin through homologous recombination or targeting of the DNA, which is introduced into genomic DNA of the primary or secondary cells at a preselected site. The present invention further relates to primary or secondary cells, referred to as homologously recombinant (HR) primary or secondary cells, produced by the present method and to uses of the homologously recombinant primary or secondary cells. The present invention also relates to a method of turning on a gene present in primary cells, secondary cells or immortalized cells of vertebrate origin, which is normally not expressed in the cells or is not expressed at significant levels in the cells.Type: GrantFiled: April 14, 2000Date of Patent: March 25, 2003Assignee: Transkaryotic Therapies, Inc.Inventors: Douglas Treco, Michael W. Heartlein, Richard F Selden
-
Patent number: 6531124Abstract: The present invention relates to transfected primary and secondary somatic cells of vertebrate origin, particularly mammalian origin, transfected with exogenous genetic material (DNA) that encodes erythropoietin or an insulinotropin (e.g., derivatives of glucagon-like peptide 1 (GLP 1)), methods by which primary and secondary cells are transfected to include exogenous genetic material encoding erythropoietin or an insulinotropin, methods of producing clonal cell strains or heterogenous cell strains that express erythropoietin or an insulinotropin, methods of gene therapy, in which the transfected primary or secondary cells are used, and methods of producing antibodies using the transfected primary or secondary cells.Type: GrantFiled: August 16, 1999Date of Patent: March 11, 2003Assignee: Transkaryotic Therapies, Inc.Inventors: Richard F Selden, Douglas Treco, Michael W. Heartlein
-
Patent number: 6472181Abstract: An implantable device having a body of matrix material made up of insoluble collagen fibrils, and disposed therewithin (a) a plurality of vertebrate cells; and (b) a plurality of microspheres each of which consists primarily of one or more of the following materials: collagen, polystyrene, dextran, polyacrylamide, cellulose, calcium alginate, latex, polysulfone, or glass.Type: GrantFiled: May 14, 1999Date of Patent: October 29, 2002Assignee: Transkaryotic Therapies, Inc.Inventor: Rochelle Mineau-Hanschke